The second phase of Monday's session on European markets brings a deterioration in investor sentiment. Despite early gains, futures based on major indices are losing value. The German DE40 is currently down 0.4%, while the EU50 is down 0.33%. The defense industry is performing poorly today, while pharmaceuticals are rebounding on the wave of favorable corporate news. No macro data of significant market importance is scheduled for release during today's session. For this reason, investors will focus on corporate news and incoming geopolitical commentary.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appSource: xStation
Current volatility observed on the broader European market. Source: xStation
The German DE40 index is down 0.50% in today's session and is testing the support zones set by the Bollinger Band moving average representing the dynamics of movements over the last 12 sessions. As long as the DE40 remains above these zones and the 50-day EMA barrier (blue curve on the chart), the overall long-term upward trend remains sustainable. The most important resistance level currently remains the range of recent historical highs. After a possible break below the aforementioned support levels, the control point on the chart may be the low from August 1, when we observed increased market volatility. Source: xStation
Market information
- European Central Bank officials intend to wait until December for the next interest rate cut, which is likely to be the last step in the current monetary policy cycle. Securities analysts are also shifting their forecasts for a possible rate cut. Postponing the decision until the end of the year gives ECB policymakers more time to assess the impact of trade disruptions resulting from the US administration's actions and new tariffs. This will allow them to analyze the economic situation after the third quarter more accurately and better estimate the directions of growth and inflation in the coming months.
- Shares in German company Rheinmetall (RHM.DE) fell by more than 4% on Monday morning on the Frankfurt Stock Exchange. The decline is due to investor concerns about the possible end of the conflict in Ukraine and talks between Trump and Putin, which could result in cuts to public spending on the arms sector.
- Danish energy company Ørsted (ORSTED.DK) announced on Monday that it was suspending the partial sale of the Sunrise offshore wind farm project in New York. Instead, the company plans to raise DKK 60 billion (approximately USD 8 billion) through a share issue. Ørsted explained that due to significant adverse changes in the US offshore wind energy market, it is no longer possible to complete the originally planned sale of shares and the related financial structure of the project on favorable terms.
- Shares in pharmaceutical company Novartis (NOVN.CH) are up more than 3% today after the company announced that both Phase III clinical trials of ianalumab have met their primary endpoints.
- GSK (GSK.UK) shares rose 0.8% after the US Food and Drug Administration (FDA) granted priority review to gepotidacin, the company's next-generation antibiotic used to treat uncomplicated gonorrhea. Potential approval would provide an effective oral treatment for a serious infection that is showing increasing resistance to currently available antibiotics. A regulatory decision is expected in December.
- Marks & Spencer (MKS.UK) shares are up 2.4% today after the company resumed accepting orders for clothing through its "click and collect" system following a nearly four-month hiatus caused by a cyberattack and data theft.
News from companies listed on the German stock exchange. Source: Bloomberg Financial Lp
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
